Edition:
India

People: Achieve Life Sciences Inc (ACHV.OQ)

ACHV.OQ on NASDAQ Stock Exchange Capital Market

10.23USD
18 Sep 2020
Change (% chg)

$-0.74 (-6.75%)
Prev Close
$10.97
Open
$13.12
Day's High
$13.46
Day's Low
$10.15
Volume
399,578
Avg. Vol
83,054
52-wk High
$48.00
52-wk Low
$4.60

Stewart, Richard 

Mr. Richard Stewart serves as Chairman of the Board, Chief Executive Officer of the Company. He has served as our Chairman, Chief Executive Officer and a director since the consummation of the Merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. in August 2017 (the “Merger”), and was Chairman and a director of Achieve Life Science, Inc., from its founding in May 2015, through the Merger. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to its acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath. The determination was made that Mr. Stewart should serve on our Board of Directors based on our belief that it is of importance that the Board of Directors have the benefit of management’s perspective and, in particular, that of the Chief Executive Officer, as well as Mr. Stewart’s prior service on boards of directors, and extensive experience and innovations in the field of biotechnology.

Basic Compensation

Total Annual Compensation, USD 500,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 296,644
Fiscal Year Total, USD 796,644

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Stewart

796,644

Anthony Clarke

589,657

John Bencich

570,547

Cindy Jacobs

580,857

Scott Cormack

317,889

Donald Joseph

--
As Of  31 Dec 2019